Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study is to assess the single- and multiple-dose pharmacokinetic (PK) profile of lenvatinib in Chinese participants with unresectable Hepatocellular Carcinoma (HCC).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02953743
Study type Interventional
Source Eisai Inc.
Contact
Status Completed
Phase Phase 1
Start date September 1, 2016
Completion date December 28, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05630937 - Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy Phase 1/Phase 2
Recruiting NCT05967143 - Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)